A Lipidomics Approach to Assess the Association Between Plasma Sphingolipids and Verbal Memory Performance in Coronary Artery Disease Patients Undertaking Cardiac Rehabilitation: A C18:0 Signature for Cognitive Response to Exercise
Restricted accessResearch articleFirst published online October 3, 2017
A Lipidomics Approach to Assess the Association Between Plasma Sphingolipids and Verbal Memory Performance in Coronary Artery Disease Patients Undertaking Cardiac Rehabilitation: A C18:0 Signature for Cognitive Response to Exercise
Early subtle deficits in verbal memory, which may indicate early neural risk, are common in patients with coronary artery disease (CAD). While exercise can improve cognition, cognitive response to exercise is heterogeneous. Sphingolipids have been associated with the development and progression of CAD, and impairments in sphingolipid metabolism may play roles in neurodegeneration and in the neural adaptation response to exercise.
Objective:
In this study, change in plasma concentrations of sphingolipids was assessed in relation to change in verbal memory performance and in other cognitive domains among CAD subjects undertaking a 6-month cardiac rehabilitation (CR) program.
Methods:
Patients with CAD (n = 120, mean age = 64±6 y, 84% male, years of education = 16±3) underwent CR with neuropsychological assessments and blood collected at baseline, 3-, and 6-months. Z-scores based on age, gender, and education were combined for verbal memory, visuospatial memory, processing speed, executive function, and global cognition tasks to calculate cognitive domain Z-scores. Plasma sphingolipid concentrations were measured from fasting blood samples using high performance liquid chromatography coupled electrospray ionization tandem mass spectrometry (LC/MS/MS). Mixed models were used to identify sphingolipids significantly associated with performance in verbal memory and other cognitive domains, adjusting for potential confounders.
Results:
A decrease in ceramide C18:0 concentration was significantly associated with improvement in verbal memory performance (b[SE] = –0.51 [0.25], p = 0.04), visuospatial memory (b[SE] = –0.44 [0.22], p = 0.05), processing speed (b[SE] = –0.89 [0.32], p = 0.007), and global cognition (b[SE] = –1.47 [0.59], p = 0.01) over 6 months of CR.
Conclusions:
Plasma ceramide C18:0 concentrations may be a sensitive marker of cognitive response to exercise in patients with CAD.
(1998) The Stationary Office (UK Government), London.
2.
KoschackJ, IrleE (2005) Small hippocampal size in cognitively normal subjects with coronary artery disease. Neurobiol Aging26, 865–871.
3.
AndréllP, JensenC, NorrsellH, EkreO, EkholmS, NorrsellU, EliassonT, MannheimerC, BlomstrandC (2005) White matter diseasein magnetic resonance imaging predicts cerebral complicationsafter coronary artery bypass grafting. Ann Thorac Surg79, 74–79; discussion 79–80.
4.
EmmrichP, HahnJ, OgunladeV, GeigerK, SchoberR, MohrFW (2003) Neuropathological findings after cardiac surgery-retrospective study over 6 years. Z Kardiol92, 925–937.
5.
KimBJ, LeeSH, KimCK, RyuWS, KwonHM, ChoiSY, YoonBW (2011) Advanced coronary artery calcification and cerebral small vessel diseases in the healthy elderly. Circ J75, 451–456.
6.
RappMA, RieckmannN, LessmanDA, TangCY, PaulinoR, BurgMM, DavidsonKW (2010) Persistent depressive symptoms after acute coronary syndrome are associated with compromised white matter integrity in the anterior cingulate: A pilot study. Psychother Psychosom79, 149–155.
7.
GeerlingsMI, AppelmanAP, VinckenKL, AlgraA, WitkampTD, MaliWP, van der GraafY; SMART Study Group (2010) Brain volumes and cerebrovascular lesions on MRI in patients with atherosclerotic disease. The SMART-MR study. Atherosclerosis210, 130–136.
8.
RobertsRO, KnopmanDS, GedaYE, ChaRH, RogerVL, PetersenRC (2010) Coronary heart disease is associated with non-amnestic mild cognitive impairment. Neurobiol Aging31, 1894–1902.
9.
VinkersDJ, StekML, van der MastRC, de CraenJ, Le CessieS, JollesJ, WestendorpRG, GusseklooJ (2005) Generalized atherosclerosis, cognitive decline, and depressive symptoms in old age. Neurology65, 107–112.
10.
BretelerMM, ClausJJ, GrobbeeDE, HofmanA (1994) Cardiovascular disease and distribution of cognitive function in elderly people: The Rotterdam Study. BMJ308, 1604–1608.
11.
LimaLM, CarvalhoMD, FerreiraCN, FernandesAP, NetoCP, GarciaJC, ReisHJ, JankaZ, PalotásA, SousaMD (2010) Atheromatosisextent in coronary artery disease is not correlated withapolipoprotein-E polymorphism and its plasma levels, butassociated with cognitive decline. Curr Alzheimer Res7, 556–563.
12.
HofmanA, OttA, BretelerMM, BotsML, SlooterAJ, van HarskampF, van DuijnCN, Van BroeckhovenC, GrobbeeDE (1997) Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer’s disease in the Rotterdam Study. Lancet349, 151–154.
SantiagoC, HerrmannN, SwardfagerW, SaleemM, OhPI, BlackSE, LanctôtKL (2015) White matter microstructural integrity is associated with executive function and processing speed in older adults with coronary artery disease. Am J Geriatr Psychiatry23, 754–763.
15.
WardlawJM, AllerhandM, DoubalFN, Valdes HernandezM, MorrisZ, GowAJ, BastinM, StarrJM, DennisMS, DearyIJ (2014) Vascular risk factors, large-artery atheroma, and brain white matter hyperintensities. Neurology82, 1331–1338.
16.
van OijenM, de JongFJ, WittemanJC, HofmanA, KoudstaalPJ, BretelerMM (2007) Atherosclerosis and risk for dementia. Ann Neurol61, 403–410.
17.
JustinBN, TurekM, HakimAM (2013) Heart disease as a risk factor for dementia. Clin Epidemiol5, 135–145.
18.
SaxtonJ, RatcliffG, NewmanA, BelleS, FriedL, YeeJ, KullerL (2000) Cognitive test performance and presence of subclinical cardiovascular disease in the cardiovascular health study. Neuroepidemiology19, 312–319.
19.
TilvisRS, Kähönen-VäreMH, JolkkonenJ, ValvanneJ, PitkalaKH, StrandbergTE (2004) Predictors of cognitive decline and mortality of aged people over a 10-year period. J Gerontol A Biol Sci Med Sci59, 268–274.
20.
EliasMF, DoreGA, DaveyA, RobbinsMA, EliasPK (2010) From blood pressure to physical disability: The role of cognition. Hypertension55, 1360–1365.
21.
SarazinM, BerrC, De RotrouJ, FabrigouleC, PasquierF, LegrainS, MichelB, PuelM, VolteauM, TouchonJ, VernyM, DuboisB (2007) Amnestic syndrome of the medial temporal type identifies prodromal AD: A longitudinal study. Neurology69, 1859–1867.
22.
SwardfagerW, HerrmannN, MarzoliniS, OhPI, SaleemM, ShammiP, KissA, CappellJ, LanctôtKL (2011) Verbal memory performance and completion of cardiac rehabilitation in patients with coronary artery disease. Psychosom Med73, 580–587.
EricksonKI, VossMW, PrakashRS, BasakC, SzaboA, ChaddockL, KimJS, HeoS, AlvesH, WhiteSM, WojcickiTR, MaileyE, VieiraVJ, MartinSA, PenceBD, WoodsJA, McAuleyE, KramerAF (2011) Exercise training increases size of hippocampus and improves memory. Proc Natl Acad Sci U S A108, 3017–3022.
25.
StanekKM, GunstadJ, SpitznagelMB, WaechterD, HughesJW, LuysterF, JosephsonR, RosneckJ (2011) Improvements in cognitive function following cardiac rehabilitation for older adults with cardiovascular disease. Int J Neurosci121, 86–93.
26.
HeynP, AbreuBC, OttenbacherKJ (2004) The effects of exercise training on elderly persons with cognitive impairment and dementia: A meta-analysis. Arch Phys Med Rehabil85, 1694–1704.
27.
KramerAF, EricksonKI, ColcombeSJ (2006) Exercise, cognition, and the aging brain. J Appl Physiol101, 1237–1242.
28.
YaffeK, BarnesD, NevittM, LuiLY, CovinskyK (2001) A prospective study of physical activity and cognitive decline in elderly women: Women who walk. Arch Intern Med161, 1703–1708.
29.
YaffeK, FioccoAJ, LindquistK, VittinghoffE, SimonsickEM, NewmanAB, SatterfieldS, RosanoC, RubinSM, AyonayonHN, HarrisTB; Health ABC Study (2009) Predictors of maintaining cognitive function in older adults: The Health ABC study. Neurology72, 2029–2035.
30.
MiddletonLE, ManiniTM, SimonsickEM, HarrisTB, BarnesDE, TylavskyF, BrachJS, EverhartJE, YaffeK (2011) Activity energy expenditure and incident cognitive impairment in older adults. Arch Intern Med171, 1251–1257.
31.
ColcombeSJ, EricksonKI, ScalfPE, KimJS, PrakashR, McAuleyE, ElavskyS, MarquezDX, HuL, KramerAF (2006) Aerobic exercise training increases brain volume in aging humans. J Gerontol A Biol Sci Med Sci61, 1166–1170.
32.
SwardfagerW, HerrmannN, MarzoliniS, SaleemM, KissA, ShammiP, OhPI, LanctôtKL (2010) Cardiopulmonary fitness is associated with cognitive performance in patients with coronary artery disease. J Am Geriatr Soc58, 1519–1525.
33.
RossR (1993) The pathogenesis of atherosclerosis: Aperspective for the 1990s. Nature362, 801–809.
34.
IchiI, NakaharaK, MiyashitaY, HidakaA, KutsukakeS, InoueK, MaruyamaT, MiwaY, Harada-ShibaM, TsushimaM, KojoS, Kisei Cohort Study Group (2006) Association of ceramides in human plasma with risk factors of atherosclerosis. Lipids41, 859–863.
35.
KinnunenPK, HolopainenJM (2002) Sphingomyelinase activity of LDL: A link between atherosclerosis, ceramide, and apoptosis?Trends Cardiovasc Med12, 37–42.
36.
JiangXC, PaultreF, PearsonTA, ReedRG, FrancisCK, LinM, BerglundL, TallAR (2000) Plasma sphingomyelin level as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol20, 2614–2618.
37.
NelsonJC, JiangXC, TabasI, TallA, SheaS (2006) Plasmasphingomyelin and subclinical atherosclerosis: Findings from themulti-ethnic study of atherosclerosis. Am JEpidemiol163, 903–912.
38.
VasantharekhaR, PriyankaHP, SwarnalingamT, SrinivasanAV, ThyagaRajanS (2016) Interrelationship between Mini-Mental State Examination scores and biochemical parameters in patients with mild cognitive impairment and Alzheimer’s disease. Geriatr Gerontol Int, in press. doi: 10.1111/ggi.12957
39.
AnsteyKJ, Ashby-MitchellK, PetersR (2017) Updating the evidenceon the association between serum cholesterol and risk of late-lifedementia: Eview and meta-analysis. J Alzheimers Dis56, 215–228.
40.
MielkeMM, MaetzlerW, HaugheyNJ, BandaruVV, SavicaR, DeuschleC, GasserT, HauserAK, Graber-SultanS, SchleicherE, BergD, Liepelt-ScarfoneI (2013) Plasma ceramide and glucosylceramide metabolism is altered in sporadic Parkinson’s disease and associated with cognitive impairment: A pilot study. PLoS One8, e73094.
HanX (2010) Multi-dimensional mass spectrometry-based shotgun lipidomics and the altered lipids at the mild cognitive impairment stage of Alzheimer’s disease. Biochim Biophys Acta1801, 774–783.
43.
MielkeMM, BandaruVV, HaugheyNJ, RabinsPV, LyketsosCG, CarlsonMC (2010) Serum sphingomyelins and ceramides are early predictorsof memory impairment. Neurobiol Aging31, 17–24.
44.
MielkeMM, BandaruVV, HaugheyNJ, XiaJ, FriedLP, YasarS, AlbertM, VarmaV, HarrisG, SchneiderEB, RabinsPV, Bandeen-RocheK, LyketsosCG, CarlsonMC (2012) Serum ceramides increase the risk of Alzheimer disease: The Women’s Health and Aging Study II. Neurology79, 633–641.
45.
MielkeMM, HaugheyNJ, BandaruVV, WeinbergDD, DarbyE, ZaidiN, PavlikV, DoodyRS, LyketsosCG (2011) Plasma sphingomyelins are associated with cognitive progression in Alzheimer’s disease. J Alzheimers Dis27, 259–269.
46.
MielkeMM, HaugheyNJ, BandaruVV, ZetterbergH, BlennowK, AndreassonU, JohnsonSC, GleasonCE, BlazelHM, PuglielliL, SagerMA, AsthanaS, CarlssonCM (2014) Cerebrospinal fluid sphingolipids, β-amyloid, and tau in adults at risk for Alzheimer’s disease. Neurobiol Aging35, 2486–2494.
47.
MielkeMM, HaugheyNJ, Ratnam BandaruVV, SchechS, CarrickR, CarlsonMC, MoriS, MillerMI, CeritogluC, BrownT, AlbertM, LyketsosCG (2010) Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss. Alzheimers Dement6, 378–385.
48.
SunY, HongF, ZhangL, FengL (2016) The sphingosine-1-phosphate analogue, FTY-720, promotes the proliferation of embryonic neural stem cells, enhances hippocampal neurogenesis and learning and memory abilities in adult mice. Br J Pharmacol173, 2793–2807.
49.
EfstathopoulosP, KourgiantakiA, KaraliK, SidiropoulouK, MargiorisAN, GravanisA, CharalampopoulosI (2015) Fingolimod induces neurogenesis in adult mouse hippocampus and improves contextual fear memory. Transl Psychiatry5, e685.
50.
Asle-RoustaM, OryanS, AhmadianiA, RahnemaM (2013) Activation of sphingosine 1-phosphate receptor-1 by SEW2871 improves cognitive function in Alzheimer’s disease model rats. EXCLI J12, 449–461.
51.
HemmatiF, DargahiL, NasoohiS, OmidbakhshR, MohamedZ, ChikZ, NaiduM, AhmadianiA (2013) Neurorestorative effect of FTY720 in a rat model of Alzheimer’s disease: Comparison with memantine. Behav Brain Res252, 415–421.
52.
KimMY, LinardicC, ObeidL, HannunY (1991) Identification of sphingomyelin turnover as an effector mechanism for the action of tumor necrosis factor alpha and gamma-interferon. Specific role in cell differentiation. J Biol Chem266, 484–489.
53.
ArboledaG, MoralesLC, BenítezB, ArboledaH (2009) Regulation of ceramide-induced neuronal death: Cell metabolism meets neurodegeneration. Brain Res Rev59, 333–346.
54.
XingHR, KolesnickR (2001) Kinase suppressor of Ras signals through Thr269 of c-Raf-1. J Biol Chem276, 9733–9741.
55.
CacciatoreF, AbeteP, MaggiS, LuchettiG, CalabreseC, ViatiL, LeoscoD, FerraraN, VitaleDF, RengoF (2004) Disability and 6-year mortality in elderly population. Role of visual impairment. Aging Clin Exp Res16, 382–388.
56.
ZivelinA, RosenbergN, PeretzH, AmitY, KornbrotN, SeligsohnU (1997) Improved method for genotyping apolipoprotein E polymorphisms by a PCR-based assay simultaneously utilizing two distinct restriction enzymes. Clin Chem43, 1657–1659.
57.
HachinskiV, IadecolaC, PetersenRC, BretelerMM, NyenhuisDL, BlackSE, PowersWJ, DeCarliC, MerinoJG, KalariaRN, VintersHV, HoltzmanDM, RosenbergGA, WallinA, DichgansM, MarlerJR, LeblancGG (2006) National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke37, 2220–2241.
58.
BenedictRH, SchretlenD, GroningerLD, DobraskiM, ShpritzB (1996) Revision of the Brief Visuospatial Memory Test: Studies of normal performance, reliability, and validity. Psychol Assess8, 145–153.
59.
GaudinoEA, GeislerMW, SquiresNK (1995) Construct validity in the Trail Making Test: What makes Part B harder?J Clin Exp Neuropsychol17, 529–535.
60.
JoyS, KaplanE, FeinD (2004) Speed and memory in the WAIS-III Digit Symbol–Coding subtest across the adult lifespan. Arch Clin Neuropsychol19, 759–767.
61.
NasreddineZS, PhillipsNA, BédirianV, CharbonneauS, WhiteheadV, CollinI, CummingsJL, ChertkowH (2005) The MontrealCognitive Assessment, MoCA: A brief screening tool for mildcognitive impairment. J Am Geriatr Soc53, 695–699.
62.
HarrisonJ, MinassianSL, JenkinsL, BlackRS, KollerM, GrundmanM (2007) A neuropsychological test battery for use in Alzheimer disease clinical trials. Arch Neurol64, 1323–1329.
63.
MielkeMM, BandaruVV, HanD, AnY, ResnickSM, FerrucciL, HaugheyNJ (2015) Factors affecting longitudinal trajectories ofplasma sphingomyelins: The BaltimoreLongitudinal Study of Aging. Aging Cell14, 112–121.
64.
AngevarenM, AufdemkampeG, VerhaarHJ, AlemanA, VanheesL (2008) Physical activity and enhanced fitness to improve cognitive function in older people without known cognitive impairment. Cochrane Database Syst Rev, CD005381.
65.
BhererL (2015) Cognitive plasticity in older adults: Effects of cognitive training and physical exercise. Ann N Y Acad Sci1337, 1–6.
66.
YoungJ, AngevarenM, RustedJ, TabetN (2015) Aerobic exercise to improve cognitive function in older people without known cognitive impairment. Cochrane Database Syst Rev, CD005381.
67.
SwardfagerW, HerrmannN, MarzoliniS, SaleemM, ShammiP, OhPI, AlbertPR, DaigleM, KissA, LanctôtKL (2011) Brain derived neurotrophic factor, cardiopulmonary fitness and cognition in patients with coronary artery disease. Brain Behav Immun25, 1264–1271.
LukTH, DaiYL, SiuCW, YiuKH, LiSW, FongB, WongWK, TamS, TseHF (2012) Association of lower habitual physical activity level with mitochondrial and endothelial dysfunction in patients with stable coronary artery disease. Circ J76, 2572–2578.
73.
KannoT, NishizakiT, ProiaRL, KajimotoT, JahangeerS, OkadaT, NakamuraS (2010) Regulation of synaptic strength by sphingosine 1-phosphate in the hippocampus. Neuroscience171, 973–980.
74.
ChatterjeeS, BedjaD, MishraS, AmuzieC, AvolioA, KassDA, BerkowitzD, RenehanM (2014) Inhibition of glycosphingolipid synthesis ameliorates atherosclerosis and arterial stiffness in apolipoprotein E-/- mice and rabbits fed a high-fat and -cholesterol diet. Circulation129, 2403–2413.
75.
HausJM, KashyapSR, KasumovT, ZhangR, KellyKR, DefronzoRA, KirwanJP (2009) Plasma ceramides are elevated in obesesubjects with type 2 diabetes and correlate with the severity ofinsulin resistance. Diabetes58, 337–343.
76.
XiaJY, HollandWL, KusminskiCM, SunK, SharmaAX, PearsonMJ, SifuentesAJ, McDonaldJG, GordilloR, SchererPE (2015) Targeted induction of ceramide degradation leads to improved systemic metabolism and reduced hepatic steatosis. Cell Metab22, 266–278.
77.
BergmanBC, BrozinickJT, StraussA, BaconS, KeregeA, BuiHH, SandersP, SiddallP, KuoMS, PerreaultL (2015) Serum sphingolipids: Relationships to insulin sensitivity and changes with exercise in humans. Am J Physiol Endocrinol Metab309, E398–E408.
78.
BergmanBC, BrozinickJT, StraussA, BaconS, KeregeA, BuiHH, SandersP, SiddallP, WeiT, ThomasMK, KuoMS, PerreaultL (2016) Muscle sphingolipids during rest and exercise: A C18:0 signature for insulin resistance in humans. Diabetologia59, 785–798.
79.
Arrieta-CruzI, Gutiérrez-JuárezR (2016) The role ofinsulin resistance and glucose metabolism dysregulation in thedevelopment of Alzheimer s disease. Rev Invest Clin68, 53–58.
FilippovV, SongMA, ZhangK, VintersHV, TungS, KirschWM, YangJ, Duerksen-HughesPJ (2012) Increased ceramide in brains with Alzheimer’s and other neurodegenerative diseases. J Alzheimers Dis29, 537–547.
82.
FabbriE, YangA, SimonsickEM, ChiaCW, ZoliM, HaugheyNJ, MielkeMM, FerrucciL, CoenPM (2016) Circulating ceramides are inversely associated with cardiorespiratory fitness in participants aged 54-96 years from the Baltimore Longitudinal Study of Aging. Aging Cell15, 825–831.
83.
BruceCR, ThrushAB, MertzVA, BezaireV, ChabowskiA, HeigenhauserGJ, DyckDJ (2006) Endurance training in obese humans improves glucose tolerance and mitochondrial fatty acid oxidation and alters muscle lipid content. Am J Physiol Endocrinol Metab291, E99–E107.
84.
DubeJJ, AmatiF, Stefanovic-RacicM, ToledoFG, SauersSE, GoodpasterBH (2008) Exercise-induced alterations in intramyocellular lipids and insulin resistance: The athlete’s paradox revisited. Am J Physiol Endocrinol Metab294, E882–E888.
85.
KasumovT, SolomonTP, HwangC, HuangH, HausJM, ZhangR, KirwanJP (2015) Improved insulin sensitivity after exercise training is linked to reduced plasma C14:0 ceramide in obesity and type 2 diabetes. Obesity (Silver Spring)23, 1414–1421.
86.
AlessenkoAV, ShupikMA, BugrovaAE, DudnikLB, ShingarovaLN, MikoyanA, VaninAF (2005) The relation between sphingomyelinase activity, lipid peroxide oxidation and NO-releasing in mice liver and brain. FEBS Lett579, 5571–5576.
BaranowskiM, Blachnio-ZabielskaAU, CharmasM, HelgeJW, DelaF, KsiążekM, DługołęęckaB, KlusiewiczA, ChabowskiA, GórskiJ (2015) Exercise increases sphingoid base-1-phosphate levels in human blood and skeletal muscle in a time- and intensity-dependent manner. Eur J Appl Physiol115, 993–1003.
89.
BaranowskiM, CharmasM, DługołęckaB, GórskiJ (2011) Exercise increases plasma levels of sphingoid base-1 phosphates in humans. Acta Physiol (Oxf)203, 373–380.
90.
HaradaJ, FoleyM, MoskowitzMA, WaeberC (2004) Sphingosine-1-phosphate induces proliferation and morphological changes of neural progenitor cells. J Neurochem88, 1026–1039.
91.
CohenRA, MoserDJ, ClarkMM, AloiaMS, CargillBR, StefanikS, AlbrechtA, TilkemeierP, FormanDE (1999) Neurocognitive functioning and improvement in quality of life following participation in cardiac rehabilitation. Am J Cardiol83, 1374–1378.
92.
BartelsC, WegrzynM, WiedlA, AckermannV, EhrenreichH (2010) Practice effects in healthy adults: A longitudinal study on frequent repetitive cognitive testing. BMC Neurosci11, 118.
93.
SwardfagerW, HerrmannN, MarzoliniS, SaleemM, FarberSB, KissA, OhPI, LanctôtKL (2011) Major depressive disorder predicts completion, adherence, and outcomes in cardiac rehabilitation: A prospective cohort study of 195 patients with coronary artery disease. J Clin Psychiatry72, 1181–1188.
94.
GraceSL, Turk-AdawiK, Santiago de Araújo PioC, AlterDA (2016) Ensuring cardiac rehabilitation access for the majority ofthose in need: A call to action for Canada. Can J Cardiol32, S358–S364.
95.
MeadH, RamosC, GranthamSC (2016) Drivers of racial and ethnic disparities in cardiac rehabilitation use: Patient and provider perspectives. Med Care Res Rev73, 251–282.
96.
SuayaJA, ShepardDS, NormandSL, AdesPA, ProttasJ, StasonWB (2007) Use of cardiac rehabilitation by Medicare beneficiaries after myocardial infarction or coronary bypass surgery. Circulation116, 1653–1662.
